Glenmark Pharmaceuticals Limited — Q4 FY24
Glenmark's Q4 FY24 consolidated revenue grew 2.1% YoY to INR 3,063 crore, with India formulation up 12.9% and ROW up 10%, but North America declined 12.4% due to lack of launches.
neutral
medium
✓ Verified against BSE filing
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Q3 FY24
India business to return to ~INR 1,000 crore quarterly run rate in Q4
After the one-time restructuring, India primary sales will normalize to ~INR 1,000 crore per quarter, growing 10-12% YoY.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1
Q3 FY24
Net cash positive by end of FY24
Proceeds from GLS divestment (~INR 5,000 crore net) will make the company net cash positive by March 2024.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1